Midostaurin
Publisher: Datamonitor Healthcare
- Description
- Contents
- Enquire
Drug Overview
Midostaurin is a multiple kinase inhibitor, which interferes with cellular signal transduction pathways. While the drug exhibits efficacy against a number of kinases, its efficacy against FLT3 is of particular relevance to AML. Patients with FLT3-mutated AML represent a key population subtype, and mutations in FLT3, specifically the FLT3- internal tandem duplication (ITD) mutation, can lead to poorer disease prognosis that in patients with wild-type FLT3.
Analyst Outlook
Midostaurin is the most advanced candidate to become the first targeted therapy to be approved for the treatment of fms-like tyrosine kinase-3 (FLT3) mutated acute myeloid leukemia (AML). Midostaurin is now being developed as an adjunctive therapy. Phase II data showed that midostaurin therapy led to hematological and blast responses in patients, with higher rates achieved in patients with FLT3-mutated AML. This study provided the rationale for Phase III development. If approved, Novartis’s experience bringing targeted therapies to the oncology market will prove useful in improving the commercial prospects for midostaurin.
TABLE OF CONTENTS
4 PRODUCT PROFILES
4 midostaurin : Acute myeloid leukemia
LIST OF FIGURES
7 Figure 1: Midostaurin – SWOT analysis for AML
8 Figure 2: Datamonitor Healthcare’s drug assessment summary for midostaurin in AML
8 Figure 3: Datamonitor Healthcare’s drug assessment summary for midostaurin in AML
LIST OF TABLES
4 Table 1: Midostaurin drug profile for acute myeloid leukemia
5 Table 2: Ongoing clinical trial development for midostaurin in AML
© Pharma Intelligence UK Ltd. This document is a licensed product and is not to be reproduced or redistributed
Do you have a subscription to Datamonitor Healthcare, Biomedtracker or Meddevicetracker? You may already have access to these reports, contact your account manager or email pharma@informabi.com for further help or assistance.
Volasertib 
Sign up to the